TREATING AGENT FOR CEREBROVASCULAR DEMENTIA
PROBLEM TO BE SOLVED: To obtain a sustained-release treating agent for cerebrovascular dementia containing an oligopeptide having TRH activity. SOLUTION: This agent contains an oligopeptide having TRH activity, e.g. a compound of the formula (X is a 4- to 6-membered heterocycle; Y is imidazol-4-yl,...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HAMAGUCHI SUNAO BUTANI TOSHIRO MIYAMOTO MASAOMI |
| description | PROBLEM TO BE SOLVED: To obtain a sustained-release treating agent for cerebrovascular dementia containing an oligopeptide having TRH activity. SOLUTION: This agent contains an oligopeptide having TRH activity, e.g. a compound of the formula (X is a 4- to 6-membered heterocycle; Y is imidazol-4-yl, 4-hydroxyphenyl or isopropyl; R and R are each H or a lower alkyl; R is H or a substitutable alkyl; Z is methylene or S) and releases the oligopeptide sustainably. The oligopeptide is preferably formulated into a buried formulation in which the oligopeptide is dispersed in a high molecular matrix, or an injection containing microspheres or microcapsules of the material obtained by crushing the buried formulation or of the oligopeptide itself. The quantity of TRH is 0.001-90% (w/w), preferably 0.01-70% (w/w) as the concentration in an inner water layer. A single dose for an adult is 0.35-35mg (0.007-0.7mg/ kg-body weight) in the case where the sustained-release agent is administered for a week in a basic administration. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JPH09208488A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JPH09208488A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JPH09208488A3</originalsourceid><addsrcrecordid>eNrjZNAOCXJ1DPH0c1dwdHf1C1Fw8w9ScHYNcnUK8g9zDHYO9XEMUnBx9QVKeTryMLCmJeYUp_JCaW4GRTfXEGcP3dSC_PjU4oLE5NS81JJ4rwAPA0sjAwsTCwtHY2LUAACADCVA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>TREATING AGENT FOR CEREBROVASCULAR DEMENTIA</title><source>esp@cenet</source><creator>HAMAGUCHI SUNAO ; BUTANI TOSHIRO ; MIYAMOTO MASAOMI</creator><creatorcontrib>HAMAGUCHI SUNAO ; BUTANI TOSHIRO ; MIYAMOTO MASAOMI</creatorcontrib><description>PROBLEM TO BE SOLVED: To obtain a sustained-release treating agent for cerebrovascular dementia containing an oligopeptide having TRH activity. SOLUTION: This agent contains an oligopeptide having TRH activity, e.g. a compound of the formula (X is a 4- to 6-membered heterocycle; Y is imidazol-4-yl, 4-hydroxyphenyl or isopropyl; R and R are each H or a lower alkyl; R is H or a substitutable alkyl; Z is methylene or S) and releases the oligopeptide sustainably. The oligopeptide is preferably formulated into a buried formulation in which the oligopeptide is dispersed in a high molecular matrix, or an injection containing microspheres or microcapsules of the material obtained by crushing the buried formulation or of the oligopeptide itself. The quantity of TRH is 0.001-90% (w/w), preferably 0.01-70% (w/w) as the concentration in an inner water layer. A single dose for an adult is 0.35-35mg (0.007-0.7mg/ kg-body weight) in the case where the sustained-release agent is administered for a week in a basic administration.</description><edition>6</edition><language>eng</language><subject>ADHESIVES ; CHEMISTRY ; DYES ; HUMAN NECESSITIES ; HYGIENE ; MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FORELSEWHERE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MISCELLANEOUS APPLICATIONS OF MATERIALS ; MISCELLANEOUS COMPOSITIONS ; NATURAL RESINS ; PAINTS ; POLISHES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>1997</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19970812&DB=EPODOC&CC=JP&NR=H09208488A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19970812&DB=EPODOC&CC=JP&NR=H09208488A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HAMAGUCHI SUNAO</creatorcontrib><creatorcontrib>BUTANI TOSHIRO</creatorcontrib><creatorcontrib>MIYAMOTO MASAOMI</creatorcontrib><title>TREATING AGENT FOR CEREBROVASCULAR DEMENTIA</title><description>PROBLEM TO BE SOLVED: To obtain a sustained-release treating agent for cerebrovascular dementia containing an oligopeptide having TRH activity. SOLUTION: This agent contains an oligopeptide having TRH activity, e.g. a compound of the formula (X is a 4- to 6-membered heterocycle; Y is imidazol-4-yl, 4-hydroxyphenyl or isopropyl; R and R are each H or a lower alkyl; R is H or a substitutable alkyl; Z is methylene or S) and releases the oligopeptide sustainably. The oligopeptide is preferably formulated into a buried formulation in which the oligopeptide is dispersed in a high molecular matrix, or an injection containing microspheres or microcapsules of the material obtained by crushing the buried formulation or of the oligopeptide itself. The quantity of TRH is 0.001-90% (w/w), preferably 0.01-70% (w/w) as the concentration in an inner water layer. A single dose for an adult is 0.35-35mg (0.007-0.7mg/ kg-body weight) in the case where the sustained-release agent is administered for a week in a basic administration.</description><subject>ADHESIVES</subject><subject>CHEMISTRY</subject><subject>DYES</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FORELSEWHERE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MISCELLANEOUS APPLICATIONS OF MATERIALS</subject><subject>MISCELLANEOUS COMPOSITIONS</subject><subject>NATURAL RESINS</subject><subject>PAINTS</subject><subject>POLISHES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1997</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNAOCXJ1DPH0c1dwdHf1C1Fw8w9ScHYNcnUK8g9zDHYO9XEMUnBx9QVKeTryMLCmJeYUp_JCaW4GRTfXEGcP3dSC_PjU4oLE5NS81JJ4rwAPA0sjAwsTCwtHY2LUAACADCVA</recordid><startdate>19970812</startdate><enddate>19970812</enddate><creator>HAMAGUCHI SUNAO</creator><creator>BUTANI TOSHIRO</creator><creator>MIYAMOTO MASAOMI</creator><scope>EVB</scope></search><sort><creationdate>19970812</creationdate><title>TREATING AGENT FOR CEREBROVASCULAR DEMENTIA</title><author>HAMAGUCHI SUNAO ; BUTANI TOSHIRO ; MIYAMOTO MASAOMI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JPH09208488A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1997</creationdate><topic>ADHESIVES</topic><topic>CHEMISTRY</topic><topic>DYES</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FORELSEWHERE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MISCELLANEOUS APPLICATIONS OF MATERIALS</topic><topic>MISCELLANEOUS COMPOSITIONS</topic><topic>NATURAL RESINS</topic><topic>PAINTS</topic><topic>POLISHES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HAMAGUCHI SUNAO</creatorcontrib><creatorcontrib>BUTANI TOSHIRO</creatorcontrib><creatorcontrib>MIYAMOTO MASAOMI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HAMAGUCHI SUNAO</au><au>BUTANI TOSHIRO</au><au>MIYAMOTO MASAOMI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>TREATING AGENT FOR CEREBROVASCULAR DEMENTIA</title><date>1997-08-12</date><risdate>1997</risdate><abstract>PROBLEM TO BE SOLVED: To obtain a sustained-release treating agent for cerebrovascular dementia containing an oligopeptide having TRH activity. SOLUTION: This agent contains an oligopeptide having TRH activity, e.g. a compound of the formula (X is a 4- to 6-membered heterocycle; Y is imidazol-4-yl, 4-hydroxyphenyl or isopropyl; R and R are each H or a lower alkyl; R is H or a substitutable alkyl; Z is methylene or S) and releases the oligopeptide sustainably. The oligopeptide is preferably formulated into a buried formulation in which the oligopeptide is dispersed in a high molecular matrix, or an injection containing microspheres or microcapsules of the material obtained by crushing the buried formulation or of the oligopeptide itself. The quantity of TRH is 0.001-90% (w/w), preferably 0.01-70% (w/w) as the concentration in an inner water layer. A single dose for an adult is 0.35-35mg (0.007-0.7mg/ kg-body weight) in the case where the sustained-release agent is administered for a week in a basic administration.</abstract><edition>6</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_JPH09208488A |
| source | esp@cenet |
| subjects | ADHESIVES CHEMISTRY DYES HUMAN NECESSITIES HYGIENE MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FORELSEWHERE MEDICAL OR VETERINARY SCIENCE METALLURGY MISCELLANEOUS APPLICATIONS OF MATERIALS MISCELLANEOUS COMPOSITIONS NATURAL RESINS PAINTS POLISHES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | TREATING AGENT FOR CEREBROVASCULAR DEMENTIA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T22%3A13%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HAMAGUCHI%20SUNAO&rft.date=1997-08-12&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJPH09208488A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |